Phase 3 Trial of Dual GLP-1/Glucagon Agonist Survodutide for Obesity Enrolls 725 Participants
The SYNCHRONIZE-1 Phase 3 trial of survodutide, a glucagon/GLP-1 dual agonist for obesity, has enrolled 725 participants across 14 countries with a mean BMI of 37.9 kg/m², with results expected after 76 weeks of treatment.
Quick Facts
What This Study Found
The SYNCHRONIZE-1 trial baseline characteristics (n=725 from 14 countries):
- Mean age: 47.1 years; 59.4% female
- Mean BMI: 37.9 kg/m²; mean waist circumference: 115.2 cm
- Geographic distribution: 47.3% North America, 21.0% Europe, 20.0% East Asia
- Obesity complications: hypertension (40.0%), dyslipidaemia (33.7%), prediabetes (30.2%)
- Mean HbA1c: 5.5%, eGFR: 93.0 mL/min/1.73 m², SBP/DBP: 127.0/82.7 mmHg
- Mean LDL cholesterol: 116.4 mg/dL; 21.8% on lipid-lowering drugs
Participants were randomized 1:1:1 to survodutide 3.6 mg, 6.0 mg, or placebo for 76 weeks. Primary endpoints are percent body weight change and achievement of ≥5% weight reduction at Week 76.
Key Numbers
How They Did This
This is a randomized, double-blind, placebo-controlled Phase 3 trial. Adults aged ≥18 with BMI ≥30 (or ≥27 with ≥1 obesity complication) without type 2 diabetes were enrolled across 14 countries. Participants were randomized 1:1:1 to weekly subcutaneous survodutide (up-titrated to 3.6 or 6.0 mg) or placebo for 76 weeks. This publication reports baseline characteristics only.
Why This Research Matters
Survodutide represents a new approach to obesity treatment by combining GLP-1 and glucagon receptor activation. While GLP-1 drugs like semaglutide reduce appetite, glucagon receptor activation may additionally boost energy expenditure and fat burning. If successful, survodutide could offer even greater weight loss than current single-mechanism drugs.
The Bigger Picture
The obesity drug landscape is rapidly expanding beyond GLP-1 monotherapy. Survodutide's dual glucagon/GLP-1 mechanism joins tirzepatide's GIP/GLP-1 approach and emerging triple agonists. Phase 2 data showed impressive weight loss, and this Phase 3 trial will determine whether survodutide can compete with or surpass existing treatments. The multinational enrollment across 14 countries reflects the global demand for effective obesity treatments.
What This Study Doesn't Tell Us
This publication reports only baseline characteristics — no efficacy or safety results are available yet. The trial excludes people with type 2 diabetes (a separate trial covers that population). The 76-week primary endpoint will provide important data, but longer-term outcomes and maintenance effects remain unknown. Comparison to other obesity drugs will require cross-trial interpretation since this is placebo-controlled.
Questions This Raises
- ?Will survodutide's dual mechanism produce greater weight loss than GLP-1-only drugs like semaglutide?
- ?Does glucagon receptor activation cause any unique safety concerns beyond those seen with GLP-1 drugs?
- ?How will survodutide compare to tirzepatide's GIP/GLP-1 dual mechanism in terms of efficacy and tolerability?
Trust & Context
- Key Stat:
- 725 participants across 14 countries Phase 3 SYNCHRONIZE-1 trial of survodutide, a novel glucagon/GLP-1 dual agonist, in adults with obesity (mean BMI 37.9) without diabetes — results pending after 76 weeks
- Evidence Grade:
- This publication reports baseline characteristics of a well-designed Phase 3 RCT. No efficacy or safety results are yet available. The trial design (double-blind, placebo-controlled, multinational) is rigorous and will provide high-quality evidence once completed.
- Study Age:
- Published in 2026 with enrollment complete, this represents one of the newest obesity drug trials. Efficacy results from SYNCHRONIZE-1 are anticipated in the near future.
- Original Title:
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
- Published In:
- Diabetes, obesity & metabolism, 28(1), 337-346 (2026)
- Authors:
- le Roux, Carel W(18), Wharton, Sean(7), Bozkurt, Biykem(3), Platz, Elke, Bleckert, Gabriele, Ajaz Hussain, Samina, Brueckmann, Martina, Startseva, Elena, Kloer, Isabel M, Kaplan, Lee M
- Database ID:
- RPEP-15491
Evidence Hierarchy
Frequently Asked Questions
How is survodutide different from semaglutide?
Survodutide activates both the glucagon receptor and the GLP-1 receptor, while semaglutide only activates GLP-1. The glucagon receptor component may boost energy expenditure and fat burning on top of the appetite suppression provided by GLP-1, potentially producing greater overall weight loss.
When will survodutide be available?
Survodutide is still in Phase 3 clinical trials. This paper reports the baseline characteristics of participants; efficacy results are expected after the 76-week treatment period. If successful, regulatory approval and clinical availability would follow, likely within a few years.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15491APA
le Roux, Carel W; Wharton, Sean; Bozkurt, Biykem; Platz, Elke; Bleckert, Gabriele; Ajaz Hussain, Samina; Brueckmann, Martina; Startseva, Elena; Kloer, Isabel M; Kaplan, Lee M. (2026). Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).. Diabetes, obesity & metabolism, 28(1), 337-346. https://doi.org/10.1111/dom.70196
MLA
le Roux, Carel W, et al. "Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).." Diabetes, 2026. https://doi.org/10.1111/dom.70196
RethinkPeptides
RethinkPeptides Research Database. "Survodutide for treatment of obesity: Baseline characteristi..." RPEP-15491. Retrieved from https://rethinkpeptides.com/research/le-2026-survodutide-for-treatment-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.